Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccineRebecca Payne, Victoria Hall, Saly Al‐Taei et al.|Cell|2021Cited by 352
A blood atlas of COVID-19 defines hallmarks of disease severity and specificityDavid Ahern, Hal Drakesmith, Zhichao Ai et al.|Cell|2022Cited by 327
A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humansMatilu Mwau, Tomáš Hanke, Inese Cebere et al.|Journal of General Virology|2004Cited by 210
A blood atlas of COVID-19 defines hallmarks of disease severity and specificityDavid Ahern, Susanna Dunachie, Zhichao Ai et al.|medRxiv|2021Cited by 35